Published in Mutat Res on November 01, 1980
DNA-protein crosslinks and p53 protein expression in relation to occupational exposure to formaldehyde. Occup Environ Med (2003) 0.99
Contribution of formaldehyde to respiratory cancer. Environ Health Perspect (1986) 0.89
Report on the Consensus Workshop on Formaldehyde. Environ Health Perspect (1984) 0.83
Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem (1987) 1.66
Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res (1990) 1.49
Proliferation dependence of topoisomerase II mediated drug action. Biochemistry (1986) 1.37
DNA double-stranded breaks in mammalian cells after exposure to intercalating agents. Biochim Biophys Acta (1981) 1.34
Qualitative and quantitative aspects of intercalator-induced DNA strand breaks. Biochim Biophys Acta (1979) 1.34
DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol (1985) 1.15
DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res (1983) 1.14
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res (1988) 1.13
Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim Biophys Acta (1978) 1.13
Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treated with cis- and trans-diamminedichloroplatinum(II). Cancer Res (1978) 1.11
Identification and characterization of a versatile retinoid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. J Biol Chem (1996) 1.10
Topoisomerase-specific drug sensitivity in relation to cell cycle progression. Mol Cell Biol (1987) 1.09
UP element-dependent transcription at the Escherichia coli rrnB P1 promoter: positional requirements and role of the RNA polymerase alpha subunit linker. Nucleic Acids Res (2001) 1.08
Differences between melphalan and nitrogen mustard in the formation and removal of DNA cross-links. Cancer Res (1978) 1.04
Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry (1989) 1.02
DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mol Pharmacol (1988) 0.99
Possible role for p34cdc2 kinase in etoposide-induced cell death of Chinese hamster ovary cells. Cancer Res (1990) 0.98
Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer (1983) 0.97
DNA topoisomerase II: a primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy. Pharmacol Ther (1987) 0.95
Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res (1987) 0.95
Comparison of microsomal drug hydroxylation in lung and liver of various species. Res Commun Chem Pathol Pharmacol (1970) 0.94
Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro. Cancer Res (1984) 0.94
Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res (1985) 0.91
Depletion of topoisomerase II in isolated nuclei during a glucose-regulated stress response. Mol Cell Biol (1989) 0.88
A pilot investigation of the psychologic functioning of patients with anticipatory vomiting. Cancer (1982) 0.88
Potentiation of bleomycin toxicity by oxygen. Cancer Treat Rep (1982) 0.87
Characterization of VP-16-induced DNA damage in isolated nuclei from L1210 cells. Biochim Biophys Acta (1984) 0.85
DNA topoisomerases in cancer therapy. Anticancer Drug Des (1987) 0.85
Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro. Cancer Res (1985) 0.84
Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine. Biochem Pharmacol (1982) 0.82
Relationship between cytotoxicity and DNA strand breakage produced by adriamycin and other intercalating agents. Int J Radiat Oncol Biol Phys (1979) 0.82
A method for assessing damage to mitochondrial DNA caused by radiation and epichlorohydrin. Mol Pharmacol (1985) 0.82
Paraquat-induced DNA damage in mammalian cells. Biochem Biophys Res Commun (1979) 0.81
Glycogen-containing neuroblastoma with clinical and histopathologic features of Ewing's sarcoma. Cancer (1978) 0.81
Inhibition of topoisomerases by fredericamycin A. Cancer Chemother Pharmacol (1989) 0.81
Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids. Cancer Chemother Pharmacol (1992) 0.80
Abrogation of etoposide-mediated cytotoxicity by cycloheximide. Biochem Pharmacol (1988) 0.79
Unconventional cancer therapy. Compr Ther (1985) 0.79
Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res (1984) 0.79
Altered function of DNA topoisomerases as a basis for antineoplastic drug action. Important Adv Oncol (1988) 0.79
Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. NCI Monogr (1987) 0.79
Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase. NCI Monogr (1987) 0.78
Sex-dependent effects of cyclic AMP on the hepatic mixed function oxidase system. Res Commun Chem Pathol Pharmacol (1973) 0.77
Isolation and purification of large quantities of DNA replication intermediates by pH step alkaline elution. Chromosoma (1979) 0.76
Etoposide-induced DNA cleavage in human leukemia cells. Cancer Chemother Pharmacol (1987) 0.76
Comparison of DNA damage by methylmelamines and formaldehyde. J Natl Cancer Inst (1981) 0.75
Impact of managed care on one training program. University of Florida at Gainesville. Arch Surg (1995) 0.75
The effects of dibutyryl cyclic AMP on the hepatic mixed function oxidase system in hormonally altered rats. Res Commun Chem Pathol Pharmacol (1973) 0.75
Allergic reaction to cyclophosphamide in a mechlorethamine-sensitive patient. Cancer Treat Rep (1977) 0.75
A study of drug-induced kinetic perturbations in the marrow of a patient with neuroblastoma. Cancer (1980) 0.75
Cytotoxicity and deoxyribonucleic acid damage associated with bromoacetate. Biochem Pharmacol (1981) 0.75
Beyond kinetics: the study of DNA damage and repair in bone marrow cells. Exp Hematol (1979) 0.75
Probenecid inhibition of methotrexate cytotoxicity in mouse L1210 leukemia cells. Cancer Treat Rep (1984) 0.75
Planning for discovery. J Fla Med Assoc (1992) 0.75
Changing prognoses in selected cancers. Med Sect Proc (1985) 0.75
Resistance to inhibitors of DNA topoisomerases. Cancer Treat Res (1991) 0.75
Effects of serum-fractions from patients with Eaton-Lambert syndrome on rat cortical synaptosomal [3H]acetylcholine release. Biochem Pharmacol (1986) 0.75
Medical schools on the fault line. J Fla Med Assoc (1994) 0.75
Properties of a purified nuclear topoisomerase from L1210 cells. Biochim Biophys Acta (1983) 0.75